Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (METAmp/Ex14∆).
暂无分享,去创建一个
R. Heist | E. Felip | A. Navarro | D. Camidge | F. Janku | A. Dowlati | Jeeyun Lee | Se-Hoon Lee | T. T. Poulsen | D. Catenacci | M. Awad | A. Martínez-Bueno | F. Nygaard | Y. Moon | K. Rohrberg | R. Dalal | D. Wood | L. Fosler | A. Yablonovitch | Helle Rudbaek